Use of Topical Cidofovir for the Treatment of Resistant Herpes Simplex Viral Infections in Post Allogeneic Hematopoietic Stem Cell Transplant Patients: Two Case Reports  by Trevino, C.M. et al.
Table 1. Incidence of side effects
Side effects 1ST % (Number) 2ND% (Number) 3RD % (Number) 4TH % (Number) 5TH % (Number) 6TH % (Number)
Number of Patient 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%) 16 (100%)
Fever & chils 4 (25%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Nausea & vomiting 0 (0%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 0 (0%)
Rash & pruritis 2 (12%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Angioedema 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Bronchospasm 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Dyspnoea 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Tumor pain 2 (12%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Pre-med
Hydrocortisone 100MG 100MG 100MG 100MG 100MG 100MG
Piriton 10MG 10MG 10MG 10MG 10MG 10MG
Paracetamol 1 GR 1 GR 1 GR 1 GR 1 GR 1 GR
Has infusion rate had to be slowed? 4 (25%) 1 (6%) 1 (6%) 0 (0%) 0 (0%) 0 (0%)
Stopped and d/c? 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Dexametasone instead of hydrocortisone 3 (19%) 3 (19%) 3 (19%) 3 (19%) 2 (12%) 1 (6%)
Methyl pred 1 G 1 (6%) 1 (6%) 1 (6%) 1 (6%) 1 (6%) 1 (6%)
Repeat pre med 2 (12%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
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UNIT-BASED CARE FOR STEM CELL TRANSPLANT (SCT) PATIENTS
REQUIRING NON INVASIVE VENTILATOR ASSISTANCE
Secola, R., Townsend, P., Killen, R. Childrens Hospital Los Angeles, Los
Angeles, CA
Stem cell transplant (SCT) recipients are part of a markedly im-
munocompromised group of patients receiving myeloablative and
intense immunosuppressive therapies. Respiratory complications
are observed throughout this process and may lead to mechanical
ventilation and transfer to an intensive care unit (ICU). Significant
morbidity and mortality is associated with these patients requiring
mechanical ventilation (Gruson et al, 1999). A less invasive means
of providing respiratory support while maintaining expert care on
the unit would appear to be beneficial. Non invasive ventilation
can offer effective respiratory support and improved gas exchange
for pediatric hematologic patients in respiratory failure (Pisastra
et al, 2004). It may also offer prevention of respiratory failure while
allowing the patients to receive optimal stem cell transplant care.
A multidisciplinary team within a licensed SCT unit took initiative
to assess the need and feasibility of maintaining patients requiring
non invasive ventilation defined as continuous positive airway pres-
sure (CPAP) or bi-level positive airway pressure (BiPAP). After
two months of collaboration with the SCTmedical director, clinical
manager, pulmonologist, intensivist, respiratory clinical manager
and therapists, a policy and procedure was developed as well as
a plan for nursing competence. The priorities included reassessment
of unit workflow and patient aggregation, clinical indications and
criteria for non invasive ventilated assistance on the SCT unit. A
nurse CPAP/BiPAP competency checklist was developed. Respira-
tory care experts shared a CPAP/BiPAP ‘‘cheat’’ sheet and provided
ongoing nursing education including in-services and hands-on dem-
onstrations for 41 unit based registered nurses. All necessary CPAP/
BiPAP equipment was stocked and is maintained in SCT unit supply
area by materials management staff. To date, two patients on BiPAP
have been cared for and maintained on the SCT unit. Ongoing reas-
sessment for any changes in CPAP/BiPAP settings or in cardiopul-
monary status on noninvasive ventilation is required to determine
if ICU care is warranted.587
QUALITY IMPROVEMENT PROCESS FOR ADVANCED PRACTICE PROFES-
SIONALS AND CREDENTIALED SKILLS
Hoffman, L.M., Krugh, D. James Cancer Hospital and Solove Research
Institute, Columbus, OH
Purpose: The purpose of this project was to assess the quality of
bone marrow aspiration and biopsies performed, possible factors
contributing to this quality, and therefore to diagnostic use.
Background: For most patients, bone marrow biopsy is a dreaded
procedure, potentially causing both physical pain and anxiety. It is
also an essentail tool in the diagnosis and classification of many he-matologic and non-hematologic diseases. As more Advanced Prac-
tice Professionals routinely perform this procedure, it is essential
to determine that their methods yield the highest quality data for in-
terpretation.
Method: Bone marrow aspiration and biopsies (n 5 121) from 23
different practitioners were evaluated for patient diagnosis, clinical
history, position at the time of sampling, body mass index, timing
of sample during treatment plan, and role of staff member. Adequacy
of the sample was determined by a Hematopathologist.
Results: 16%of bonemarrow aspiration and 19.2% of bonemarrow
biopsies were considered inadequate, although 100% were inter-
preted by the Hematopathologist. Inadequate bone marrow aspira-
tion was associated with a higher patient BMI (p 5 0.015) and
lower bone marrow cellularity (p 5 0.0001). Inadequate bone mar-
row biopsy was not affected by the patient’s BMI (p 5 0.85), degree
of bone marrow cellularity (p 5 0.75), and there was no correlation
(R2 5 0.02) between patient’s BMI and biopsy core length. Bone
marrow biopsy mean/median length was 10mm, with 12% being
considered inadequate length (\5mm), 11.7% fragmented and
14.2% having aspiraton artifact. 48% of inadequate bonemarrow bi-
opsies were noted to have cortical boone, cartilage and/or bone. No
other factors were causative for an inadequate specimen. Overall Ad-
vance Practice Professional performance was equal to or better than
other levels of practitioner.
Conclusions: Advanced Practice Professionals contribute greatly to
the care of patients with cancer, in small part, by the procedures they
become skilled at performing. Bone marrow aspiration and biopsy is
a significant tool in the arsenal used for assessment of these diseases.
It is critical that optimal specimens be provided to aid in critical
treatment decisions. A quality improvement process, such as one
used in this project, can be utilized for any advanced level procedure
to assure that quality specimens are obtained, and ultimately correct
decisions are made in patient care.588
USE OF TOPICAL CIDOFOVIR FOR THE TREATMENT OF RESISTANT HER-
PES SIMPLEX VIRAL INFECTIONS IN POST ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT PATIENTS: TWO CASE REPORTS
Trevino, C.M., Westmoreland, M.D., Hosing, C. Univeristy of Texas
M.D. Anderson Cancer Center, Houston, TX
Post allogeneic hematopoietic stem cell transplant patients are at
risk for the development of infections due to their immuncompro-
mised state. The probability of reactivation of herpes simplex infec-
tions is more than 70 percent post transplantation [1]. Current
standard treatment modalities include the use of intravenous, oral,
and topical medications. The current American Society of Bone
Marrow Transplantation Society guidelines for managing resistant
herpes simplex infections recommend Foscarnet as the treatment
of choice with Cidofovir as an alternative [2]. There are times how-
ever, when the herpes simplex virus will develop resistance to the cur-
rent standard therapy and require the initiation of novel treatment
S364 Poster Session IIapproaches. Two individual case presentations will be presented of
patients treated at our institution who developed resistant herpes
simplex infections. The clinical course and treatment history will
be provided. These cases also necessitated a multidisciplinary ap-
proach that included wound care, pain service and infectious disease.
In the both cases, the patients were initiated on topical Cidofovir, an
institutional compounded formulation. One patient was prescribed
a topical cream application and the other a topical oral solution. It
was observed that acute renal failure developed within a short time
frame after initiation of the topical Cidofovir in both cases. The
treatment of herpes simplex infections in the immuncompromised
patient can be challenging for the clinical provider especially when
resistance has developed. Additionally, it is debilitating and painful
to the patient. The efficacy and safety of topical Cidofovir warrants
further careful investigation as demonstrated by the clinical course of
these two cases.589
COMPLEX DISCHARGE COORDINATION: IMPROVING HOSPITAL FLOW,
FAMILY SATISFACTION AND SAFETY
Baker, A.L., Berger, S.J., Bessler, L., Rigby, S., Spear, S., Gold, J.,
Friend, L., Lake, M., Boughner, A., Borich, A.M., Flesch, L.,
Freeman, B., Lawrence, J., Maas, D., Turner, K., Liming, B. Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
Purpose:Development of a highly-reliable, efficient discharge pro-
cess between the inpatient Blood and Marrow Transplant (BMT)
program and Home Health Care at Cincinnati Children’s Hospital
Medical Center.
Aim: That 80% of all patients discharged from the inpatient unit
meet the goal of being discharged on or before 1600.
Background:The BMTunit averages 25 discharges per month with
themajority utilizing theHomeCare department.We identified that
the day of discharge for new BMT patients was often chaotic with
accruing issues that resulted in delayed discharges.
Method and Design: Beginning in July 2009, discussions began
among key members of the team to improve the discharge process
for families. Data was collected and evaluated on a monthly basis.
Reasons for late discharges were evaluated, utilizing a Pareto Chart,
which demonstrated multiple offending factors. A series of small
tests of change were performed monthly with multiple revisions
using PDSA (Plan/Do/Study/Act) cycles.
Findings: Factors impacting discharge included the need for con-
tinuing education, scheduled treatments on day of discharge, trans-
portation issues, incomplete comprehensive discharge summary, and
timeliness in filling outpatient oral prescriptions. PDSA cycles im-
plemented included the ‘‘Pathway to Discharge’’ educational tool
for families, ‘‘Interdisciplinary Pathway to Discharge’’ tool for staff,
discharge family conferences and use of an online prediction tool.
Beginning in July 2009, 71% of patients were being discharged by
1600. The latest evaluated data shows that 91% of patients are being
discharged by the goal of 1600.590
TRIAGE AT THE SCCA TRANSPLANT CLINIC
Stener, C.L. Seattle Cancer Care Alliance, Seattle, WA
Purpose: Triage is the process of assessing patient’s clinical com-
plaints and symptoms and then setting a priority for treatment based
on the acuity of their condition. In the BMT population, it is essen-
tial to provide 24/7 accessibility of nursing staff on the telephone and
in person for patients to ask questions, be assessed and to provide
treatment if necessary.
Background: Our clinic is located in a large urban area which is af-
filiated with an academic teaching hospital and a pediatric hospital.
We perform greater than 520 transplants a year which consist of au-
tologous, synergenic, and allogenic (related, unrelated and cord
blood) transplants. Daily there is an average acute census of 160
outpatients.
Intervention: Inmost cases patients can remain on an outpatient ba-
sis during transplant conditioning. We infuse stem cell products in
the OPD except bone marrow and cord blood. Patients are admitted
based on clinical need, and then discharged on very liberal clinicalcriteria. When hospitalized the length of stay averages 1-3 weeks.
By doing this there’s a higher level of acuity with outpatients who
need immediate access to care at all times. To accommodate these
patients we have developed a robust triage process. There is 24/7 ac-
cess for care, when the OPD closes patients or the caregiver can call
the inpatient facility where a nurse is designated to field these calls
which will provide the needed support or intervention. If seen in
the late evening or early morning the assigned nurse will fax a report
to the OPD to explain why the patient was seen, if follow up is
needed or if the patient was admitted.
Evaluation: Triage has enhanced our ability to provide immediate
patient support and intervention. As a result of this triage process
the length of stay in the hospital has been shortened. Additionally,
this process has increased the confidence and competence of patients
and care givers for outpatient care management following a BMT.591
IMPROVING INSTITUTIONAL TIMELINE FROM FORMAL DONOR SEARCH
TO TRANSPLANTATION
Risley, G.L.10124, Krugh, D.M.10124 1OSUMC - James Cancer Hospital,
Columbus, OH
Purpose/Background: The National Marrow Donor Program
(NMDP) 2007 Transplant Center Performance report showed that
the turnaround time for our Center ranged from 58 to 3303 days
from formal search to transplantation. We had no data available to
determine the cause of the variability and the large expanse from for-
mal search to transplant. It was determined that strategies needed to
be developed to identify and improve the factors that influenced our
timeline.
Approach/Method: A performance improvement project to track
data on all formal searches was initiated. This data included the
date the formal search was initiated, the date of donor identification,
and the date of transplantation. The data was also linked to the dis-
ease being treated and individual physicians to identify any opportu-
nities for improvement. The Medical Director initiated an
intervention with any outlier physicians who had ongoing searches.
In addition, beginning in 2009 the reason the patient did not proceed
to transplant was tracked. Patients in a remission who had an identi-
fied donor were reviewed to see if they were proceeding to trans-
plant. Those not proceeding until a relapse occurred had their
searches closed. Finally, the Coordinators were reassigned so that
only one Coordinator was responsible for all activities related to
NMDP searches. This streamlined the communication with the
NMDP and the physicians.
Results: After tracking the data for one year we have shown modest
improvement. The March, 2010 NMDP Transplant Center Perfor-
mance report demonstrated that our days from formal search to
transplant had decreased to 33-749 days. From 2007-2009 the num-
ber of days from formal search to donor identification remained sta-
ble. The number of patients having a donor identified who then
proceeded to transplant has increased from 36% to 62%. Mean
days from initiation of donor search to transplant has decreased by
36% and from donor identification to transplant has decreased by
66%.
Conclusions: Utilization of a donor tracking spread sheet has
helped to identify a patient population whose timing of formal search
needs reviewed before implementing. We will continue to maintain
one Search Coordinator as communication with the NMDP and
physicians is a key factor. There is a plan to continue tracking to en-
sure that improvement is maintained and to try and identify other
areas that could be improved upon.592
SYMPTOM ASSESSMENT AND OPTIMAL MANAGEMENT OF OCULAR
GRAFT VERSUS HOST DISEASE
Heffernan, M.J. Fred Hutchinson Cancer Research Center, Seattle, WA
Ocular graft versus host disease is a common complication follow-
ing allogeneic hematopoietic stem cell transplantation affecting
more than 40-60% of patients with chronic graft versus host disease.
Common ocular structures affected include the eyelid, lacrimal
gland, conjunctiva and cornea. Infiltration of the lacrimal glands
